Sheet	1	of	1
JIICCL		U	

			, /					Silee	٠ ١٥
FORM	PTO-1	449 FEB 1 6 20	25 S	U.S. Dept. of Commerce	Atty D	ocket No.		Seria	l No.
		13		Patent and Trademark Office	P1726	R1P1		09/7	13,425
				ratest and trademark office	Appli	cant			ł
LIST	OF DIS	CLOSURE CONTENTS	APPLICANT			a, L.		<u> </u>	
(Use several sheets if necessary)					Filing	Date Nov 2000		Group 1644	1
					15 800 2000				
				U.S. PATENT DOCUMENTS		····			
xaminer		Decument Number	Date	Name		Class	Subr	dass	Filing Date
nitials		Document Number		Ravetch, J.		Om.33	1000		Timing Date
200	165	2001/0036459	01.11.01 04.09.03	Presta et al.		<u></u>		-	
- 11	166	2003/0166868 2004/0191244A1	30.09.04	Presta, L.			_	-	
- 1 1	167	2004/0191244A1 2004/0228856A1	18.11.04	Presta, L.		-		-	
- / 1	168	4,490,473	25.12.84	Brunhouse .					
-	170	5,419,904	30.05.95	Irie, R.			_	-	
	171	5,731,168	24.03.98	Carter et al.			_	-	
-	172	6,676,927	13.01.04	Ravetch, J.			_		
	173	6,737,056	18.05.04	Presta, L.				_	
ر ا	174	6,821,505	23.11.04	Ward, E.			_	_	
		0,022,000	<u> </u>	OSURES (Including Author, Title, Date,	 Dortino	nt Panes etc	.1		
- N I		Antibodies. A Lab		, Harlow and Lane, New York: Cold				tory p	ps. 321 (1988)
Bull	175			,					
2		Fridman, W., "Fc	receptors and	immunoglobulin binding factors"	FASEB .	Journal 5(12):2	684-26	90 (Sep 1991)
	176								
		Fundamental Immur	ology, Paul, W	. E., 2nd edition, New York:Rave	n Pres	s pps. 60	and 6	1 (198	19)
4	177			•					
	Kim et al., "Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn" 178 European Journal of Immunology 29(9):2819-2825 (Sep 1999)								
					al Bub	Hahing Lt	d no	g 21	and 23 (1986)
1 1	Male, D. Immunology, An Illustrated Outline, London:Gower Medical Publishing Ltd. pps. 21 and 23 (1986)								
-1:		Martin et al., "C	rvstal structu	re at 2.8 A of an FcRn/heterodim	eric F	c complex:	mech	anism	of ·
	180	pH-dependent bind	ling" <u>Molecular</u>	Cell 7(4):867-877 (Apr 2001)		_			
-}-		Newkirk et al., '	Rheumatoid fac	tor avidity in patients with rhe	umatoi	d arthriti	s: 10	entifi	cation of
(181	101inian) Tamunala	···· 15/51.250-2	with disease parameters and with 57 (Sep 1995)		_			
V .		Williams et al	"Heteroclitic	polyclonal and monoclonal anti-G nuced in Gm(a-), Gm(g-) IgG by in	m(a) a	nd anti-Gm	(g) I	uman i	rheumatoid
₩ -	182	aggregation Jour	cnal of Immunol	ogy 149(5):1817-1824 (Sep 1, 199	2)				.,pool
						<u>.</u>	_		
									•
-			·						
	-								
Examine)r	David	aSue	enders 0	ate Con	sidered	5/	3/0	75
*Examir	er: In	itial if reference consid	lered, whether or r	not citation is in conformance with MPEP upy of this form with next communication	609; dra	aw line throu	gh cit	ation	
11 IN/L	•	STIME OF THE PARTY		T) and latter than from wellingshoomers					

Sheet	1	of	1

•	, ,		OIPE						Shee	t <u>1</u>	of <u>1</u>
FORM	PTO-1	1449	AUG 0 3 20	NC 37	U.S. Dept. of Commerce Patent and Trademark Office	1 1	Oocket No. 6R1P1		Seria	l No. 13,425	
LIST	OF DIS	SCLOSURES CITED B	1.		Patent and Trademark Office		icant ta, L.				
(U	se sev	eral sheets if necessary) RADEM			_	Date 5 Nov 2000		Group 1644		
				F	OREIGN PATENT DOCUMENTS		-		-		
Examiner Initials		Document Number	Date		Country		Class	Subc	lass	Transla Yes	ation No
DWG.	164	WO 00/42072	20.07.00	PCT			_	_	_		

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
Som	164	WO 00/42072	20.07.00	PCT			
					•		
		·] ·				
	•						
							:
		•		·		-	
				•			
			•				
						•	
			. •				
			•				
		ļ		·			
Examiner				l Da	ite Considered		ļ
and the POI	<u>ک</u>	tacid	u ya	cender Da	ر	5/14/	اری

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.